SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (9947)12/9/2010 7:39:22 AM
From: IRWIN JAMES FRANKEL6 Recommendations  Read Replies (4) of 10345
 
Tysabri anecdote continues:

I am replying to the series of reports of my wife who has RRMS moving to Tysabri from Copaxone so anyone who wants to can read the series.

At this point treatment with T has gone on for ~32 months.

Karen was treated with C for many years before it failed. During C treatment Karen did fairly well. But exacerbations did not stop (longer intervals between them) suggesting that the disease remained active.

Every MRI, those toward the end of C treatment and those during the T treatments showed new disease activity - that is until the last one a few weeks ago. We just got the latest MRI results and were told that it showed no new lesions.

I am not sure I believe it - though I would like to.

My wife will be in the trials testing for JCV which requires blood draws. Hopefully that will go a long way to identify patients that are at high risk for PML and those who are not.

ij
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News